News From Multiple Perspectives

Opposing Singtel's Dual Listing of Nxera on Nasdaq and SGX

Published July 29, 2026 at 11:02 PM UTC

Authored by
Every article published on DirectionFreeNews undergoes editorial review by our editorial team. Our editors research publicly available information from multiple trusted news organizations, compare differing perspectives, verify key facts, and publish balanced summaries intended to help readers better understand important events. Our editorial process is designed to reduce editorial bias by considering multiple reputable sources rather than relying on a single viewpoint

While the proposed dual listing of Nxera on Nasdaq and SGX aims to enhance the company's global visibility and access to capital, it also presents several challenges and risks that warrant caution.

The dual listing process involves navigating the regulatory requirements and compliance standards of both exchanges, which can be complex and time-consuming. This may divert management's focus from core business operations and strategic initiatives.

Additionally, the costs associated with dual listing, including listing fees, legal expenses, and ongoing compliance costs, can be substantial. For a company like Nxera, which is still expanding its operations, these financial burdens could impact profitability and shareholder value.

The dual listing could also expose Nxera to increased scrutiny from a broader range of investors and analysts, potentially leading to greater volatility in its stock price. This heightened exposure may not align with the company's long-term strategic goals and could result in short-term market pressures.

Given these considerations, it is important for Singtel and Nxera to carefully evaluate the potential benefits against the associated risks and costs before proceeding with the dual listing.